Muscarinic acetylcholine receptors

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Muscarinic acetylcholine receptors (mAChRs) are G protein-coupled receptors mediating diverse physiological processes.
• Five subtypes (M1-M5) exist, differentially coupled to G proteins (Gq/11 or Gi/o) to regulate intracellular signaling pathways.
• Previous pharmacological studies were limited by non-selective ligands, hindering subtype-specific functional elucidation.

Purpose of the Study:

• To review recent advances in the structural and functional characterization of muscarinic acetylcholine receptors.
• To discuss the pharmaceutical development of muscarinic receptor ligands.
• To highlight the therapeutic potential of mAChRs in various diseases.

Main Methods:

• Review of recent literature on muscarinic acetylcholine receptor research.
• Analysis of findings from gene targeting approaches to elucidate receptor subtype functions.
• Examination of current pharmaceutical development strategies for mAChR ligands.

Main Results:

• Odd-numbered mAChRs (M1, M3, M5) activate phospholipase C via Gq/11, leading to Ca2+ mobilization.
• Even-numbered mAChRs (M2, M4) inhibit adenylyl cyclase and activate potassium channels via Gi/o.
• Gene targeting has successfully differentiated the specific roles of each mAChR subtype.
• Muscarinic receptors are emerging as key therapeutic targets for conditions such as dry mouth, incontinence, and COPD.

Conclusions:

• Understanding mAChR subtype-specific functions is crucial for developing targeted therapies.
• Advances in structural biology and gene targeting have significantly improved our knowledge of mAChRs.
• Targeting muscarinic receptors offers promising therapeutic avenues for a range of human diseases.